Nuria Oliva-Jorge graduated from Institut Quimic de Sarria, Universitat Ramon Llull (Barcelona, Spain) with a Bachelor of Science in Organic Chemistry. She then received her PhD in Medical Engineering and Medical Physics (MEMP) at the Harvard-MIT Division of Health Sciences and Technology (HST); training under the guidance of Prof Elazer Edelman and Prof Natalie Artzi, Nuria focused on the development of a novel adhesive hydrogel and its use as a model platform to understand how disease microenvironment affects material performance and how to leverage those cues to attain tumor cell-selective delivery of chemotherapy in a local and sustained manner. She then spent one year at Brigham and Women's Hospital (Harvard Medical School) as a NIH Ruth L. Kirschstein post-doctoral fellow within the Organ Design and Engineering Training Program (ODET) at Brigham and Women’s Hospital (Harvard Medical School).
Nuria then joined the Almquist Lab at Imperial College London in 2017, where she is developing novel DNA nanotechnology-based approach for modulating bone regeneration.
For more information, visit Nuria's website
et al., 2019, Biologically inspired, cell-selective release of aptamer-trapped growth factors by traction forces, Advanced Materials, Vol:31, ISSN:0935-9648
et al., 2017, Designing Hydrogels for On-Demand Therapy, Accounts of Chemical Research, Vol:50, ISSN:0001-4842, Pages:669-679
et al., 2016, Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model, Nature Materials, Vol:15, ISSN:1476-1122, Pages:1128-+
et al., 2016, Local microRNA delivery targets Palladin and prevents metastatic breast cancer, Nature Communications, Vol:7, ISSN:2041-1723
Conde J, Oliva N, Artzi N, 2016, Revisiting the 'One Material Fits All' Rule for Cancer Nanotherapy, Trends in Biotechnology, Vol:34, ISSN:0167-7799, Pages:618-626